REGEN-COV Phase 3 Trial Improves Survival in Patients Hospitalized with Severe COVID-19
June 17, 2021
A Phase 3 RECOVERY trial in the UK found that Regeneron’s REGEN-COV antibody treatment reduced the risk of death by 20% in patients who had not mounted their own immune response against COVID-19. In addition, among patients without their own immune response, the median duration of hospital stay was 4 days shorter in the REGEN-COV group, and there was a greater proportion of patients discharged by 28 days. Research has also shown that the treatment remains effective against the main variants of COVID-19 in the United States.
REGEN-COV is a mix of two monoclonal antibodies known as casirivimab and imdevimab. These antibodies block the infection ability of SARS-COV-2, the virus that causes COVID-19.
The results of the RECOVERY trial demonstrate that REGEN-COV can “alter the course of COVID-19 infection from prevention to very early infection, all the way through to when patients are on a ventilator in the hospital.” Regeneron is working with the FDA to expand its current EUA to other populations such as hospitalized patients.